Abstract 4145435: Diagnostic Accuracy of Non-Invasive Assessments for Detecting Cardiac Transplant Rejection: A Meta-Analysis

Le résumé fourni par la source

Background: After heart transplantation, endomyocardial biopsy (EMBx) is the standard diagnostic modality for acute rejection (AR). However, EMBx is invasive with some limitations to conventional histological interpretation. Non-invasive assessments, such as cardiac magnetic resonance Imaging (MRI) and donor-derived cell-free DNA (dd-cfDNA) assays, have emerged as viable methods for diagnosing acute rejection. This study aims to assess the diagnostic performance of cardiac MRI and dd-cfDNA for evaluating acute cardiac transplant rejection. Method PubMed and Web of Science were searched for relevant publications reporting on the use of dd-cfDNA or cardiac MRI for the detection of acute cardiac transplant rejection defined as acute cellular rejection (ACR) and/or antibody-mediated rejection (AMR), with EMBx as the reference standard. Pooled sensitivity, specificity, and hierarchical modeling-based summary receiver-operating characteristic (sROC) curves were calculated. Results: Out of 725 screened papers, 23 studies were included (10 studies with cardiac MRI and 13 studies with dd-cfDNA). Five studies considered only ACR as a rejection criterion, while eighteen studies included both ACR and AMR. The sensitivity and specificity for detecting acute transplant rejection were 0.68 (95% CI: 0.58-0.77) and 0.82 (95% CI: 0.74-0.88) for dd-cfDNA, and 0.79 (95% CI: 0.66-0.88) and 0.72 (95% CI: 0.62-0.81) for cardiac MRI. The areas under the hierarchical modeling-based sROC curves were 0.82 (95% CI: 0.78-0.85) for dd-cfDNA and 0.82 (95% CI: 0.79-0.85) for cardiac MRI. While there was no significant difference in the sROC between dd-cfDNA and cardiac MRI (p = 0.959), cardiac MRI had significantly higher sensitivity (p < 0.001) and dd-cfDNA had significantly higher specificity (p = 0.001) ( Figure ) Conclusion: dd-cfDNA and cardiac MRI demonstrated comparable high diagnostic accuracy for acute cardiac transplant rejection. Given the high sensitivity of cardiac MRI and the high specificity of dd-cfDNA, combining these two non-invasive modalities may provide an effective screening strategy to detect acute cardiac transplant rejection and reduce the need of EMBx.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.